The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity					
CIV (Eilor ID Number)	Previous	□ None	Entity Type		
CIK (Filer ID Number)	Names	None	Entity Type		
0001716947	Leisure Acquis	sition Corp.	Corporation		
Name of Issuer			Limited Partnership		
Ensysce Biosciences, Inc.			Limited Liability Company		
Jurisdiction of Incorporation/Org	ganization		H		
DELAWARE			☐ General Partnership		
Year of Incorporation/Organization			Business Trust		
X Over Five Years Ago			Other (Specify)		
Within Last Five Years (Spec	cify Year)				
Yet to Be Formed					
2. Principal Place of Business	and Contact Information				
Name of Issuer					
Ensysce Biosciences, Inc.					
Street Address 1		Street Address 2			
7946 IVANHOE AVE,		SUITE 201			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer		
LA JOLLA	CALIFORNIA	92037	(858) 263-4196		
3. Related Persons					
Last Name	First Name		Middle Name		
Kirkpatrick	D		Lynn		
Street Address 1	Street Address 2				
7946 Ivanhoe Ave, Suite 201					
City	State/Province/Cou	intry	ZIP/PostalCode		
La Jolla	CALIFORNIA		92037		
Relationship: X Executive Office	er X Director Promoter				
Clarification of Response (if Neo	essary):				
Last Name	First Name		Middle Name		
Gower	Bob				
Street Address 1	Street Address 2				
7946 Ivanhoe Ave, Suite 201					
City	State/Province/Cou	ıntry	ZIP/PostalCode		
La Jolla	CALIFORNIA		92037		
Relationship: Executive Office	er X Director Promoter				
Clarification of Response (if Neo	essary):				
Last Name	First Name		Middle Name		
Chang	William				
Street Address 1	Street Address 2				
7946 Ivanhoe Ave, Suite 201					
City	State/Province/Cou	ıntry	ZIP/PostalCode		
La Jolla	CALIFORNIA		92037		
Relationship: Executive Office	er X Director Promoter				
Clarification of Response (if Nec	essary):				

Last Name	First Name	Middle Name
Benton	Andrew	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201		
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):	_	
Last Name	First Name	Middle Name
Martin	Steve	madio Namo
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201	Olicel Address 2	
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director		92037
	Fromotei	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Levin	Adam	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201		
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Rosebraugh	Curtis	madio Namo
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201	Stroot / tudi coo Z	
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director	=	72037
	I Tomoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Humphrey	David	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201		
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: X Executive Officer Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Rauch	Lee	
Street Address 1	Street Address 2	
7946 Ivanhoe Ave, Suite 201		
City	State/Province/Country	ZIP/PostalCode
La Jolla	CALIFORNIA	92037
Relationship: Executive Officer X Director		
Clarification of Response (if Necessary):	_	
4. Industry Group		
auou y oroup		

Agriculture	Health Care	Retailing		
Banking & Financial Services	Biotechnology	Restaurants		
Commercial Banking	Health Insurance	Technology		
Insurance	Ц	Computers		
Investing	Hospitals & Physicians			
Investment Banking	Pharmaceuticals	Telecommunications		
Pooled Investment Fund	X Other Health Care	Other Technology		
Is the issuer registered as	Manufacturing	Travel		
an investment company under the Investment Company	Real Estate	Airlines & Airports		
Act of 1940?	Commercial	Lodging & Conventions		
YesNo	Construction	Tourism & Travel Services		
Other Banking & Financial Services				
Business Services	REITS & Finance	Uther Travel		
Energy	Residential	Other		
Coal Mining	Other Real Estate			
Electric Utilities	_			
Energy Conservation				
Environmental Services				
Oil & Gas				
Other Energy				
5. Issuer Size				
Revenue Range OR	Aggregate Net	Asset Value Range		
No Revenues	No Aggregate	e Net Asset Value		
\$1 - \$1,000,000	\$1 - \$5,000,0	000		
\$1,000,001 - \$5,000,000	\$5,000,001 -	\$25,000,000		
\$5,000,001 - \$25,000,000	\$25,000,001	- \$50,000,000		
\$25,000,001 - \$100,000,000	\$50,000,001	- \$100,000,000		
Over \$100,000,000	Over \$100,00	00,000		
X Decline to Disclose	Decline to Disclose			
Not Applicable Not Applicable				
6. Federal Exemption(s) and Exclusion(s)	Claimed (select all that app	oly)		
	Investme	nt Company Act Section 3(c)		
	Section 3	(c)(1) Section 3(c)(9)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3	(c)(2) Section 3(c)(10)		
Rule 504 (b)(1)(i)	Section 3			
Rule 504 (b)(1)(ii)				
Rule 504 (b)(1)(iii) X Rule 506(b)	Section 3	(c)(4) Section 3(c)(12)		
Rule 506(c)	Section 3	(c)(5) Section 3(c)(13)		
Securities Act Section 4(a)(5)	Section 3	(c)(6) Section 3(c)(14)		
	Section 3	(c)(7)		
7 7 650				
7. Type of Filing				
X New Notice Date of First Sale 2023-02-0	Pirst Sale Yet to Occur			
Amendment				
8. Duration of Offering				

Does the Issuer intend this offering to last more than one year?	s X No	
9. Type(s) of Securities Offered (select all that apply)		
Equity	Pooled Investment Fund Interests	
Debt	Tenant-in-Common Securities	
X Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or Other FAcquire Security	Right to Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combination to or exchange offer?	ransaction, such as a merger, acquisition Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number None	
H.C. Wainwright & Co., LLC	375	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None	
None	None	
Street Address 1 430 PARK AVENUE	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
NEW YORK	NEW YORK	10022
State(s) of Solicitation (select all that apply) Check "All States" or check individual States X	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$2,816,073 USD or Indefinite		
Total Amount Sold \$2,816,073 USD		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
Warrants to purchase common stock to investors for up to 3,571,431 shares at \$\\$1.05/\share in connection with a 2/2/2023 registered direct offering.	\$0.715/share and to designees of H.C. Wainwright & Co., LLC for up	to 250,000 shares at
14. Investors		
Select if securities in the offering have been or may be sold to person such non-accredited investors who already have invested in the offer Regardless of whether securities in the offering have been or may be total number of investors who already have invested in the offering:	ering. be sold to persons who do not qualify as accredited investors, er	
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders fees check the box next to the amount.	expenses, if any. If the amount of an expenditure is not known,	provide an estimate and
Sales Commissions \$210,000 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
16. Use of Proceeds		
Provide the amount of the gross proceeds of the offering that has been executive officers, directors or promoters in response to Item 3 above.		
\$0 USD Estimate		

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the
 accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Ensysce Biosciences, Inc.	/s/ Lynn Kirkpatrick	Dr. Lynn Kirkpatrick	President and CEO	2023-03-01

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.